CASI Pharmaceuticals (NASDAQ:CASI) spotted trading -62.30% off 52-week high price. On the other end, the stock has been noted 25.22% away from the low price over the last 52-weeks. The stock changed -8.86% to recent value of $1.44. The stock transacted 273671 shares during most recent day however it has an average volume of 188.05K shares. The company has 106.08M of outstanding shares and 51.11M shares were floated in the market.
On March 16, 2020, CASI Pharmaceuticals (NASDAQ:CASI) a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, provided a business update.
Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, commented, We made significant progress in 2019 with the August launch of EVOMELA® and ended the year with $4.1 million in revenues. We also in-licensed our other key programs, including CNCT-19 (CD19 CAR-T) and CID-103 (anti-CD38 Mab) strengthening CASI’s position in the hematology/oncology therapeutic area. In 2019, we completed the buildout of our China infrastructure including in the marketing and sales, medical affairs, regulatory and clinical development areas. Despite a slow-down in the first quarter of 2020 due to the coronavirus outbreak (COVID-19), we will continue to drive sales of EVOMELA so that we can fully serve the patients that can benefit from EVOMELA, the only commercially available melphalan in China.
Dr. He continued, We are pleased that the CNCT19 (CD19 CAR-T) B-NHL Phase I study is progressing at anticipated pace. Based on previous data, we are excited about the advancement of this very promising therapy, and despite the initial slow-down, we look forward to advancing this study. We remain on track with our other clinical trials planned for 2020.
Its earnings per share (EPS) expected to touch remained -85.10% for this year. CASI has a gross margin of 5.00%.
According to the most recent quarter its current ratio was 10.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of -24.40% from the mean of 20 days, -42.50% from mean of 50 days SMA and performed -52.54% from mean of 200 days price. Company’s performance for the week was -21.31%, -36.84% for month and YTD performance remained -53.40%.